BT6487 - you are getting your trials mixed up.
It was the FSGS Phase 2a result that shot the share price from 38c to a high of 77c which was then torn down by the DKD Phase 2 results.
On-going understanding of the positive FSGS Phase 2a was then lost in the 'noise' of the reaction to the DKD results just 6 weeks later. Illogically, the FSGS trial got tarnished with the same brush.
The March interim reading is ONLY to do with the so-far positive FSGS trial - not the so-far neutral DKD trial.
This confusion over the trials is why DXB has been such a great opportunity.
I expect an even bigger response with a positive outcome for Phase 3 than was experienced with the Phase 2a - partly because it is from a much lower base (than the 38c immediately prior to the Phase 2a results announcement).
BT6487 - you are getting your trials mixed up. It was the FSGS...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $208.8M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.5¢ | $124.7K | 336.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 40429 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 49100 | 7 |
View Market Depth
| Last trade - 11.30am 02/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |